06.13.25 -- Reactive To Proactive: A Major Shift In The Fight Against Alzheimer's

On Business of Biotech, Thomas Levenson, MIT professor and author of So Very Small: How Humans Discovered The Microcosmos, Defeated Germs — And May Still Lose The War Against Infectious Disease talks about what he learned in the writing of So Very Small, how cultural and political forces shape scientific progress, and what it means for drug developers, public health officials, and patients everywhere. Brought to you by Avantor.

To preserve the quality of care and build a more effective approach to trial design, a sponsor must consider their approach to patient recruitment and enrollment early and often.

Learn more about a major workshop intended to empower biotech innovators with tools, mentorship, and connections to accelerate regenerative medicine breakthroughs from research to real-world impact.

Screen-Printed Innovative Drug Technology can produce oral, transdermal, and implantable dosage forms while ensuring heterogeneous distribution of active ingredients.

Join leading clinical experts as they debunk the top myths about eCOA in 2025, separating fact from fiction to help clinical operations, procurement, and data management teams make smarter decisions.

Numerous factors impact a drug safety program, but proper management of three key elements drives success while creating a scalable drug safety model.